Digital Biomarkers for Alzheimer’s Disease

阿尔茨海默病的数字生物标志物

• 批准号: 10495200
• 负责人: IHAB M HAJJAR
• 金额: $ 4.09万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-30 至 2022-07-18
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10495200
• 关键词: Acoustics; Aging; Alzheimer disease detection; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer’s disease biomarker; Amyloid; Amyloid beta-Protein; Applications Grants; Area Under Curve; Artificial Intelligence; Autobiography; Autopsy; Biological Markers; Brain; Categories; Cerebrospinal Fluid; Classification; Clinical; Cognition; Cognitive; Complex; Consumption; Data; Dementia; Development; Diagnosis; Diagnostic; Disease; Disease Progression; Early identification; Elderly; Foundations; Framingham Heart Study; Future; Hippocampus (Brain); Hypertension; Image; Impaired cognition; Impairment; Individual; Light; Machine Learning; Magnetic Resonance Imaging; Measurement; Measures; Methodology; Methods; Natural Language Processing; Nerve Degeneration; Neurofibrillary Tangles; Neuropsychology; Online Systems; Participant; Pathologic; Performance; Phase; Phenotype; Positron-Emission Tomography; Predictive Value; Reporting; Research; Scanning; Semantics; Specificity; Speech; Spinal Puncture; Stress; Sum; Symptoms; Testing; Time; Voice; Weight; Work; automated speech recognition; base; biomarker signature; cerebral atrophy; clinical decision-making; cognitive testing; cohort; density; diagnostic accuracy; digital; early detection biomarkers; follow-up; functional status; hippocampal atrophy; improved; in vivo; innovation; insight; lexical; mild cognitive impairment; neurofilament; neuroimaging; novel; pre-clinical; programs; smartphone Application; success; tau Proteins; tau-1; technology validation; tool

Alzheimer’s disease (AD) is marked by progressive neuropathological changes that begin decades before cognitive and functional symptoms, and thus efforts have been focused on developing innovative tools and biomarkers for early identification of pre-dementia stages. To date, clinical ability to identify those with pre-dementia stages of AD has been limited and requires expensive (amyloid PET) or invasive (lumbar puncture) testing. However, subtle changes in connected speech may be detectable years before overt disease symptoms present. Our team has developed an approach that uses machine learning and natural language processing combined with advanced acoustic phonetic and lexical-semantic analyses. Preliminary data show promise in identifying AD biomarker status and predicting 2-year cognitive progression. In the proposed study, we leverage our success in collecting cerebrospinal fluid (CSF) biomarkers, neuroimaging and detailed cognitive phenotyping combined with audio recordings of participants in the Brain Stress, Hypertension and Aging Research Program cohort. This cohort, now in its third year of follow-up, consists of 400 individuals 50 years or older with normal cognition or mild cognitive impairment. We plan to extend this cohort of 400 participants for 3 more years to collect additional waves of voice recordings, cognitive assessments, follow-up CSF biomarkers and neuroimaging. Our overarching hypothesis is that the derived novel features reflecting poor lexical- semantic connectedness or acoustic perturbations are significantly different between biomarker-positive and -negative participants, have better diagnostic performance with regards to the ATN framework than traditional cognitive tests and can track disease progression. The Specific Aims are: 1) Determine the accuracy of the derived digital biomarkers in detecting in-vivo AD pathology and ATN classification in the B- SHARP cohort; 2) Investigate the association of the derived digital biomarkers with disease progression and cognitive decline; and 3) Investigate the ability of repeated measurement of the digital biomarkers to track disease progression. This project will provide needed insight into the use of non-invasive digital biomarkers to improve the ability to detect and track longitudinal changes in cognitive and functional status in AD and will set the foundation for a future larger pivotal study.

阿尔茨海默病（AD）的特点是几十年前开始的进行性神经病理改变